New data from two phase III trials, DISCOVER-1 and DISCOVER-2, of guselkumab demonstrated improvements in multiple clinical outcomes in patients with active psoriatic arthritis

The data which formed basis of supplemental Biologics License Application submission to FDA showed improvements in multiple clinical outcomes including joint symptoms, skin symptoms, soft tissue inflammation, physical function and reduction in radiographic progression at week 52

SPS commentary:

Guselkumab is currently licensed for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. An application to extend the licence in EU to cover treatment of active psoriatic arthritis was filed in Oct 2019.

Biospace Inc.